CERT Stock Analysis
CE
Uncovered
Certara Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Princeton, New Jersey and currently employs 1,150 full-time employees. The company went IPO on 2020-12-11. The firm is focused on producing medicines for patients using biosimulation software, technology, and services to transform traditional drug discovery and development. The firm builds its biosimulation technology on the first principles of biology, chemistry, and pharmacology with mathematical algorithms that model how medicines and diseases behave in the body. The company offers an integrated, end-to-end platform for its clients, including various biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries. The company also provides an artificial intelligence (AI)-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Its product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text and images, offers AI capabilities to support decisions in all phases of drug development.